Stay updated on Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. This represents a minor site-version update and does not alter the study details, eligibility criteria, or user interactions.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedUpdated the study's Locations information: a new Locations section is added and lists Kentucky, Minnesota, Missouri, and Nebraska. The previously separate state location entries (Kentucky Locations, Minnesota Locations, Missouri Locations, Nebraska Locations) have been removed in the new revision (v3.3.3).SummaryDifference0.5%

- Check55 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.2; no substantive content changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRemoved the notice about potential disruptions due to a lapse in government funding; the ClinicalTrials.gov page content and study details remain intact. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedSponsor attribution (Alliance Foundation Trials, LLC.) and related headers were removed from the Study Details page, and a General Poster Session entry was deleted.SummaryDifference0.2%

- Check76 days agoChange DetectedChanges appear limited to formatting and visual layout with no changes to study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page.